Chemotherapy works by attacking cells that are actively dividing. Since cancer cells divide far more frequently than most healthy cells, they bear the brunt of the damage. The drugs disrupt key steps in the process of cell division, either by damaging DNA, starving cells of the building blocks they need to copy themselves, or physically preventing a cell from splitting into two. Most chemotherapy regimens use a combination of drugs that attack different stages of this process, making it harder for cancer to survive.
Why Dividing Cells Are Vulnerable
Every cell in your body goes through a predictable sequence of steps when it divides, called the cell cycle. It copies its DNA, checks for errors, assembles the machinery to pull itself apart, and finally splits. Chemotherapy drugs are designed to sabotage one or more of these steps. Some drugs damage DNA so severely that the cell can’t complete its copy. Others wait until the cell is in the final act of splitting and jam the molecular scaffolding that pulls the two halves apart. The cell, unable to finish dividing, self-destructs.
This is why chemotherapy hits cancer especially hard. A tumor’s defining trait is uncontrolled division. At any given moment, a large proportion of cancer cells are mid-cycle and exposed to attack. Healthy cells divide too, but most of them spend long stretches in a resting state where they’re far less susceptible.
The Major Classes of Chemotherapy Drugs
There are several broad families of chemotherapy drugs, each with a different strategy for killing cancer cells.
- Alkylating agents were among the first cancer drugs developed and remain some of the most widely used. They work by chemically binding to a cell’s DNA strands, creating crosslinks and breaks that prevent the cell from copying its genetic code. These drugs tend to be most effective against slower-growing cancers.
- Antimetabolites mimic the nutrients a cell needs to build new DNA. The cell absorbs the fake building blocks, incorporates them into its genetic machinery, and essentially starves because it can’t complete the replication process with defective parts.
- Mitotic inhibitors (many of which are derived from plants) block the final stage of cell division. When a cell tries to physically split in two, these drugs prevent the internal scaffold from forming, trapping the cell in its most vulnerable moment.
Oncologists frequently combine drugs from different classes in a single regimen. By attacking the cell cycle at multiple points simultaneously, combination therapy reduces the chance that any cancer cells slip through.
How Chemotherapy Is Given
The most common route is intravenous infusion, where the drug enters your bloodstream through a vein and circulates throughout the body. This systemic approach is designed to reach cancer cells wherever they may be, including microscopic clusters that haven’t been detected yet. Some chemotherapy drugs come as pills or liquids you swallow at home, and a few are applied as creams for skin cancers.
When a tumor is confined to a specific area, doctors sometimes deliver chemotherapy directly to that region. This can mean infusing the drug into a single artery that feeds the tumor, or placing it directly into a body cavity like the abdomen or bladder. Localized delivery concentrates a higher dose at the tumor site while reducing exposure to the rest of the body.
The choice of delivery method depends on the type of cancer, how advanced it is, and your overall health. Some cancers simply don’t respond well to systemic chemotherapy and require a more targeted approach.
Treatment Cycles and Rest Periods
Chemotherapy is almost always given in cycles: a period of treatment followed by a period of rest, repeated over weeks or months. A typical cycle might involve one to several days of drug administration followed by two to three weeks off. The rest period exists for a specific biological reason. Your healthy cells need time to recover from the collateral damage of treatment, particularly the cells in your bone marrow that produce blood. Without that break, your immune system and blood cell counts would drop to dangerous levels.
The number of cycles you need depends on the type and stage of cancer, how well the tumor responds, and which drugs are being used. Some treatment plans run for three or four cycles, others for six or more. Blood tests between cycles help your oncology team decide whether your body has recovered enough to proceed on schedule.
How Doctors Calculate Your Dose
Chemotherapy dosing is based on your body surface area, a measurement calculated from your height and weight. Research has shown that dosing by body surface area produces more consistent drug levels in the blood than dosing by weight alone. This matters because chemotherapy has a narrow therapeutic window: too little and the drug won’t control the cancer, too much and the toxicity becomes dangerous. Your medical team recalculates the dose before each cycle, adjusting for any changes in your weight or how well you tolerated the previous round.
Why Healthy Cells Get Caught in the Crossfire
Chemotherapy can’t perfectly distinguish a cancer cell from a healthy one. It targets rapid division, and a few types of healthy cells divide quickly too. The cells lining your digestive tract, the blood-producing cells in your bone marrow, and the cells in hair follicles are the most common casualties. That’s why nausea, lowered blood counts, and hair loss are the hallmark side effects of chemotherapy.
Hair loss is a particularly well-studied example. The cells at the base of a growing hair follicle are among the fastest-dividing cells in the body. Chemotherapy drugs trigger programmed cell death in these rapidly multiplying cells, and the damage extends to the pigment-producing cells nestled among them. This is why hair often grows back a different texture or shade after treatment ends. The damage is temporary because the stem cells that regenerate hair follicles are deeper and divide more slowly, so they tend to survive.
Bone marrow suppression is the side effect that most directly affects treatment scheduling. When your marrow can’t produce enough white blood cells, red blood cells, or platelets, you become vulnerable to infections, anemia, and bleeding. The rest periods between cycles are specifically designed to let your marrow rebuild.
How Cancer Cells Resist Treatment
One of the biggest challenges with chemotherapy is that cancer cells can become resistant to it. This happens in two ways. Some cancer cells carry molecular changes from the very beginning that make them insensitive to a particular drug. Even a small cluster of resistant cells within a tumor can survive treatment and eventually regrow. This built-in resistance is common.
Other times, cancer cells adapt while treatment is underway. They acquire new molecular changes that allow them to dodge the drug’s effects. One well-understood escape route involves pump proteins on the cell surface. Healthy cells naturally have these pumps to expel toxins, but cancer cells can ramp up production of them, actively pushing chemotherapy drugs back out before they can do damage.
Resistance can also emerge through changes in how genes are switched on and off, without any alteration to the DNA code itself. Chemical tags attached to DNA or to the proteins that package it can silence genes that make the cell vulnerable, or activate genes that help it survive. This is one reason oncologists use drug combinations: when one drug is blocked by a resistance pathway, the second drug can shut down that escape route. Studies have shown that treatment with only one drug in an effective pair often fails because an alternate survival pathway compensates.
The Blood-Brain Barrier Problem
The brain presents a unique challenge for chemotherapy. A tightly sealed layer of cells lines the blood vessels in the brain, forming a barrier that blocks nearly all large molecules and about 98% of small molecules from crossing into brain tissue. This protective barrier is essential for keeping toxins out of the brain, but it also keeps most chemotherapy drugs out.
Brain tumors do partially compromise this barrier, creating leaky blood vessels around the tumor. But the leakiness is uneven, and the same pump proteins that help cancer cells resist chemotherapy elsewhere are also present in these blood vessel walls, actively expelling drugs that do manage to cross. This means that even when a drug reaches the brain, maintaining a high enough concentration to actually kill tumor cells is extremely difficult.
Chemotherapy vs. Targeted Therapy
Traditional chemotherapy casts a wide net, attacking all rapidly dividing cells. Newer targeted therapies take a different approach. They block specific molecules that cancer cells depend on to grow and survive, such as particular enzymes, growth factor receptors, or signaling proteins that drive tumor development. Because targeted therapies are designed to interfere with molecular features more unique to cancer cells, they tend to cause different (and sometimes fewer) side effects than traditional chemotherapy.
That said, targeted therapies aren’t a replacement for chemotherapy in every situation. Many treatment plans combine both approaches, using chemotherapy to kill the bulk of dividing cancer cells while a targeted drug blocks the specific pathway the tumor relies on for growth. The two strategies complement each other, and the best combination depends entirely on the molecular profile of the cancer being treated.